tbuckley/cabot-search huggingface dataset:
P215 The incremental disease burden associated with the persistence of morning, daytime and night-time symptoms in chronic obstructive pulmonary disease patients
Authors: A Munoz, J Bailey, R Wood, A Ribera, J Nuevo
Journal: Thorax (2016)

<h3>Introduction</h3> The current Global Initiative for Chronic Obstructive Lung Disease Strategy makes limited references to the variability of chronic obstructive pulmonary disease (COPD) symptoms according to the time of day patients experience symptoms, on awakening/morning, in the daytime and at night-time; therefore it’s unclear whether specific treatment approaches are needed. <h3>Aims</h3> To establish the association between time of day of symptoms and the burden experienced by patients; as measured by validated patient-reported outcomes (PROs), healthcare resource utilisation (HRU) and physician-perceived impact of COPD on patients’ lives. <h3>Methods</h3> Data were taken from four waves (2012–2016) of the Respiratory Disease Specific Programme (DSP); cross-sectional surveys of COPD patients in France, Germany, Italy, Spain, and the UK. Patients were defined as suffering from symptoms on awakening/morning (M), in the daytime (D), at night-time (N) or combinations of these according to physician-reported time of day of symptoms within the last 4 weeks. Kruskal-Wallis tests assessed statistical significance of outcomes across patient groups. Outcomes included HRU in the last 12 months, EQ-5D-3L with visual analogue scale, Jenkins Sleep Evaluation Questionnaire, COPD Assessment Test, activity impairment (measured by the work productivity and activity impairment questionnaire), and physician-reported impact COPD has on the patient’s sleep. <h3>Results</h3> In total, 8185 patients receiving treatment were analysed; 25% suffered no symptoms, 16% D only, 17% M/D only, 6% D/N only, 4% M, N or M/N only and 32% M/D/N. Across the four DSP waves, patients suffering any M, D or N symptoms ranged from 46%−64%, 67%–77% and 38%–47%, respectively. All outcomes differed significantly across patient groups (Table 1). In general, M/D/N patients utilised the most healthcare resources, suffered more exacerbations requiring emergency room visits or hospital admissions, had higher activity impairment and reported worse quality of life and sleep, whilst asymptomatic patients utilised the least resources and reported the best quality of life and sleep. The remaining groups suffered similar levels of burden. <h3>Conclusions</h3> In this analysis, patients experiencing morning, daytime and night-time symptoms have the worst PROs and more disease burden. Clearer recognition of symptom burden and an individualised treatment approach may be warranted for these patients.
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT
Authors: Juliane Paul, Maurice Soujon, Antje M. Wengner, Sabine Zitzmann-Kolbe, Andrea Sturz, Katja Haike, Koh Hui Keng Magdalene, Sze Huey Tan, Martin Lange, Soo Yong Tan, Dominik Mumberg, Soon Thye Lim, Karl Ziegelbauer, Ningshu Liu
Journal: Cancer Cell (2017)
Activation of Non-Canonical Wnt Pathway in Human Mesenchymal Cells Affects Osteogenic Differentiation: A Potential Target in Multiple Myeloma Microenvironment
Authors: Nicola Giuliani, Simona Colla, Paola Storti, Gaetano Donofrio, Marina Bolzoni, Sabrina Bonomini, Luisa Galla, Gabriella Sammarelli, Marcellina Mangoni, Vittorio Rizzoli
Journal: Blood (2008)
Hepatic artery radioembolization (HARE) in the management of progressive metastatic neuroendocrine tumors (NETs): A survival and biochemical response analysis in geriatric (G) and young (Y) populations.
Authors: K. S. Jahangir, R. Majoria, J. Hagan, P. Boudreaux, S. Varughese, Y. Wang, B. C. Boulmay, R. Campeau, E. Woltering, L. B. Anthony
Journal: Journal of Clinical Oncology (2011)

e19727 Background: HARE with Y-90 SIR-Spheres is a treatment (Rx) option for NET patients (pts); however, survival statistics, biochemical responses (BR) and factors influencing outcomes are lacking. The objectives of this study are: 1) to determine whether age (G ≥ 60yrs vs Y< 60yrs) influences overall survival (OS) and progression free survival (PFS); 2) to calculate biochemical response (BR); 3) to identify predictive factors in NET pts receiving HARE. Methods: A retrospective chart analysis of consecutive HARE NET pts at Ochsner Medical Center Kenner was performed. Demographic, serial pre- and post-Rx (1,6,12,18 mos) Karnofsky performance status (KPS), biochemical (5-HIAA, chromogranin A, pancreastatin, neurokinin A [NKA]) and radiographic response data were collected and OS, PFS and BR calculated. Results: Between 12/2004 and 8/2010, 73 NET pts (37 small bowel [SB], 12 pancreas [P], 6 rectum, 18 other) with a median age (range) of 60.4 yrs (39-75) underwent HARE. Survivals statistics are shown in the table. No differences in OS (p=0.759) and PFS (p=0.767) were seen in G vs Y pts. Primary site was not associated with OS (p=0.373), SB had better PFS (p<0.001). Higher Ki-67 index had lower PFS, Hazard ratio (HR)=1,488,691, p=0.002. NKA level at 6 mos was directly proportional to radiographic progression, HR=1.05, p=0.047. Pre-Rx KPS was greater for alive pts, median KPS=85 vs median KPS=72 for pts who died, p=0.040. Conclusions: HARE is equally effective in all age groups and is independent of primary site. SB primary has a greater PFS than P. The Ki-67 index is inversely proportional to PFS. Higher pre-Rx KPS correlates with better outcomes. NKA level at 6 mos is predictive of progressive disease. Mean OS (mos) Mean PFS (mos) 12 mos % (N) 18 mos % (N) N=73 55.2 10.6 97.1 (67) 92.3 (60) Age, yrs (N) SB P SB P SB P SB P All (49) 51.4 56.4 13.7 8.0 94.3 (35) 100 (12) 94.1 (34) 90.9 (11) <60 (39) 51.3 54.7 17.7 8.9 88.2 (17) 100 (8) 87.5 (16) 100 (8) ≥60 (34) 51.4 59.6 9.6 6.5 100 (18) 100 (4) 100 (18) 66.6 (3) ≥65 (24) 46.5 59.6 10.6 6.5 100 (13) 100 (4) 100 (13) 66.6 (3) ≥70 (12) 49.2 110.5 12.9 8.9 100 (7) 100 (1) 100 (7) 100 (1)
P281 Annual change in pulmonary function in asbestosis
Authors: S Clarke, J Hoyle
Journal: Thorax (2016)

<h3>Introduction</h3> Asbestosis is commonly considered to be associated with slowly progressive pulmonary fibrosis. However, there is limited recent data to support this opinion. We set out to analyse the change in pulmonary function test (PFT) over time in a cohort of outpatients with asbestosis. <h3>Methods</h3> Patients were identified retrospectively from a pool of clinic patients who had consented to participate in research. The diagnosis of asbestosis had been made on CT findings, history of asbestos exposure, exclusion of other causes of interstitial lung disease and agreement at occupational MDT. The PFT data from tests closest to the time of initial diagnosis were compared to the most recent PFT results. Parameters assessed were FEV<sub>1</sub>, FVC, VC, TLC and KCO. The values were expressed as percentage predicted to ensure adjustment for age, weight etc. Annual change was calculated by dividing the total change by the number of years elapsed between PFT. Smoking status was also documented. <h3>Results</h3> 57 patients were identified with a diagnosis of asbestosis. 9 had only had 1 set of PFT (awaiting follow-up) and hence were excluded leaving 48 patients. The mean time difference between PFT was 3.0 years (range 0.2–6.1 years). In 21 cases TLC had not been measured in one or both PFT and in 10 KCO had not been measured. <h3>Conclusions</h3> As expected baseline FEV<sub>1</sub> decreased with increased smoking exposure. The other parameters at baseline were lower in those with the highest smoking exposure with the exception of TLC which was more varied. The greatest rate of change was seen in KCO% predicted, consistent with previous research. Unexpectedly the groups demonstrating the maximal decline in KCO were those with a low (&lt;20 pack year) smoking history (7.2% annual decline) followed by lifelong non-smokers (3.9% annual decline). Those with the heaviest smoking history showed a lower rate of decline in all parameters compared to both non-smokers and the population as a whole. KCO and TLC were not performed in those with the most severe disease due to breathlessness, thus these results are likely to be an under-estimate of lung function changes.
Regeneration of bone using nanoplex delivery of FGF-2 and BMP-2 genes in diaphyseal long bone radial defects in a diabetic rabbit model
Authors: Behnoush Khorsand, Nate Nicholson, Anh-Vu Do, John E. Femino, James A. Martin, Emily Petersen, Brian Guetschow, Douglas C. Fredericks, Aliasger K. Salem
Journal: Journal of Controlled Release (2017)
P3.02c-007 Assessment of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer
Authors: Anne Steino, Guangan He, Beibei Zhai, Jeffrey Bacha, Shun Lu, Dennis Brown, Mads Daugaard, Zahid Siddik
Journal: Journal of Thoracic Oncology (2017)
P2.03a-032 Palliative Chemotherapy with Oral Metronomic Vinorelbine in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unsuitable for Chemotherapy
Authors: Giuseppe Banna, Giuseppe Anile, Marine Castaing, Maurizio Nicolosi, Salvatore Strano, Francesco Marletta, Stefania Calì, Rohit Lal
Journal: Journal of Thoracic Oncology (2017)
P1.05-069 Stage II NSCLC Treated with Non-Surgical Approaches: A Multi-Institution Report of Outcomes
Authors: Shaan Dudani, Xiaofu Zhu, Daniel Yokom, Andrew Yamada, Cheryl Ho, Jason Pantarotto, Natasha Leighl, Tinghua Zhang, Paul Wheatley-Price
Journal: Journal of Thoracic Oncology (2017)
MA17.10 YES1 Kinase is a New Therapeutic Target in Non-small Cell Lung Cancer
Authors: Jackeline Agorreta, Irati Garmendia, Maria Pajares, Daniel Ajona, Daniel Alameda, Carmen Behrens, Ignacio Wistuba, Ruben Pio, Luis Montuenga
Journal: Journal of Thoracic Oncology (2017)
P1.02-035 Concomitant Driver Mutation Determines Tumor Growth in EGFR Mutation-Positive Lung Adenocarcinoma
Authors: Kazuhiro Nagayama, Takahiro Karasaki, Hideki Kuwano, Jun-Ichi Nitadori, Masaaki Sato, Masaki Anraku, Hirokazu Matsushita, Kazuhiro Kakimi, Jun Nakajima
Journal: Journal of Thoracic Oncology (2017)
Abstract A35: Olaparib causes premature loss of cohesion in cancer cells
Authors: Eva Kukolj, Tanja Kaufmann, Amalie E. Dick, Robert Zeillinger, Daniel W. Gerlich, Dea Slade
Journal: Clinical Cancer Research (2017)

Abstract Although it has been decades since PARP inhibitors were initially discovered and various clinical trials have been performed, their mode of action in killing tumor cells subsequent to PARP inhibition is still not fully understood. We have recently identified poly(ADP-ribosyl)ation (PARylation) as a new post-translational modification of the cohesin complex, a key player in chromosome segregation during mitosis. We investigated the effect of PARP inhibition on mitosis in a panel of cells of cancer (cervical, breast, ovarian) and normal tissue origin. We treated cancerous and non-cancerous cell lines labelled with chromatin markers with a selected set of PARP inhibitors and imaged them with fluorescence live microscopy. Out of 5 tested inhibitors, a well-known and clinically relevant PARP inhibitor olaparib, induced strongest perturbations in mitotic progression. Olaparib induced a delay in entering anaphase, problems aligning chromosomes at the metaphase plate and premature loss of cohesion (cohesion fatigue) after a prolonged metaphase arrest. Cohesion fatigue, leading to cell death, was observed in cancer cell lines exhibiting S-phase stalling or G2/M arrest with increased protein levels of PARP1. Olaparib is known to entrap PARP1 at replication forks and thereby perturb replication fork movement. While its addition before the onset of mitosis did not result in mitotic defects, addition of olaparib only in S-phase was sufficient to cause mitotic phenotypes. Our results indicate that PARP inhibition by olaparib in S phase has downstream effects on mitotic progression. PARP1 RNAi in addition to olaparib treatment rescues the cohesion fatigue phenotype, suggesting that entrapment of PARP1 at the replication fork upon its inhibition is the main cause of cohesion fatigue. Cohesion fatigue was observed only in highly aneuploid cancer cells that are described to have an increased rate of chromosome mis-segregation. In conclusion, higher susceptibility of aneuploid cancer to cohesion fatigue and cell death upon olaparib treatment relative to normal cells would support its use as anti-mitotic chemotherapy. Citation Format: Eva Kukolj, Tanja Kaufmann, Amalie E. Dick, Robert Zeillinger, Daniel W. Gerlich, Dea Slade. Olaparib causes premature loss of cohesion in cancer cells. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr A35.
Allogeneic Stem Cell Transplantation in Patients with Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndromes: Effect of Patient Characteristics and Treatment History.
Authors: Francesco Spina, Emilio Paolo Alessandrino, Lucia Farina, Raffaella Milani, Francesca Bonifazi, Massimo Bernardi, Roberto Lucksh, Franca Fagioli, Paolo Corradini
Journal: Blood (2010)
S116 Hot decaf: a rct comparing home treatment and inpatient care in copd exacerbations selected by low risk decaf score
Authors: C Echevarria, T Hartley, J Gray, C Muirhead, A Van-Wersch, J Miller, J Steer, AJ Simpson, GJ Gibson, SC Bourke
Journal: Thorax (2016)

<h3>Background</h3> The DECAF score is a robust predictor of early mortality in patients admitted with an acute exacerbation of COPD (AECOPD),<sup>1</sup> and should be routinely documented on admission.<sup>2</sup> Of importance, 45–53% of admitted patients are low risk by DECAF (0–1), therefore potentially suitable for hospital at home (HAH). Compared to existing criteria, selection by DECAF would allow inclusion of substantially more patients, some with higher medical dependency. <h3>Methods</h3> In a randomised controlled trial (RfPB PB-PG-0213-30105), patients admitted with an AECOPD were allocated to HAH or usual care (UC). Readmissions for AECOPD within 90 days were managed according to the allocated arm, provided they were low risk (DECAF = 0–1). Eligibility criteria included: primary diagnosis AECOPD, DECAF score 0–1, age 35 or more, 10 or more cigarette pack-year history and obstructive spirometry (FEV1/VC less than 70%). Total bed days and readmissions over 90 days, and 14 and 90 day mortality were captured. At day 14, patients were asked for their preferred place of care during future exacerbations of similar severity. <h3>Results</h3> Between June 2014 to January 2016 118 of 207 eligible patients were randomised: female = 56/118 (52.5%), mean age (SD) = 69.8 (10.2), mean FEV1% predicted (SD) = 43.9 (17.6) and coexistent pneumonia = 24/118 (20.3%). At 14 days, 105/117 (90%) patients expressed a preference for HAH. Median bed days were 4 days lower in the HAH arm (p = 0.001), with no difference in mortality or readmissions. <h3>Conclusions</h3> Selection for HAH by low risk DECAF score is safe, clinically effective, preferred by most patients, reduces total bed days and is a suitable option for up to 50% of admitted patients. <h3>References</h3> Steer J, <i>et al</i>. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. <i>Thorax</i> 2012;<b>67</b>(11):970–6. BTS national audit report 2015.
P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: Baohui Han, Kai Li, Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Jianxing He, Yuankai Shi, Yin Cheng, Weiqiang Chen, Xiuwen Wang, Yi Luo, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Jianying Zhou, Yinlan Chen, Donglin Wang, Xin Zhou, Yan Yu, Liming Chen, Anwen Liu, Jianjin Huang, Cheng Huang, Bangwei Cao, Jun Chen, Rui Ma, Zhuang Yu, Cuimin Ding, Hongbing Wang
Journal: Journal of Thoracic Oncology (2017)
P3.02a-006 Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
Authors: Mark Awad, Cristina Mastini, Rafael Patino, Luca Mologni, Claudia Voena, Lara Mussolin, Stacy Mach, Anika Adeni, Christine Lydon, Pasi Jänne, Roberto Chiarle
Journal: Journal of Thoracic Oncology (2017)
P3.02b-059 The Role of Epidermal Growth Factor Receptor in the Onset of Skeletal Related Events in Non-Small Cell Lung Cancer
Authors: Shu-Mei Huang, Jin -Ji Yang, Huajun Chen, Xiao-Yan Bai, Qing Zhou, Hai-Yan Tu, Yi Long Wu
Journal: Journal of Thoracic Oncology (2017)
S17 The burden of idiopathic pulmonary fibrosis in the united kingdom: a retrospective, matched cohort study
Authors: M Storm, I Tran, H Strongman, J Fredriksson, T Maher
Journal: Thorax (2016)

<h3>Background</h3> Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia which primarily affects older adults, for which very few treatments have existed. While attention has been paid to quantifying the rising incidence and prevalence of the disease, little has been done to quantify the impact of this disease on NHS resources and how this impact varies by setting. <h3>Objective</h3> This study aims to identify health care utilisation patterns in the United Kingdom (UK) following IPF diagnosis. <h3>Methods</h3> The Clinical Practice Research Datalink (CPRD) GOLD dataset for general practitioner office visits and the linked Hospital Episode Statistics (HES) datasets were analysed, covering the time period from January 1, 2000 to June 30, 2015. A matched cohort analysis was conducted, and frequency counts and regression analyses were used to quantify raw healthcare resource utilisation and understand the proportion of the utilisation that is attributable to IPF. <h3>Results</h3> The results of this study indicate that IPF patients have significantly higher healthcare utilisation patterns than non-IPF patients. The regression results indicate that IPF leads to roughly 2.2 times as many GP visits, 8.7 times as many inpatient hospitalizations, and 2.4 times as many outpatient hospital visits per year (all p-values &lt;0.0001), as well as increased referrals, prescriptions, and, in the post-diagnosis period, inpatient stay duration. Additionally, healthcare utilisation amongst these patients is dramatically higher in the year prior to IPF diagnosis, a pattern not witnessed in the matched cohort. <h3>Conclusions</h3> IPF imposes a significant burden on the NHS despite its rare prevalence. IPF patients experience an across the board increase in healthcare utilisation, but the burden is particularly acute in the inpatient hospital setting. Additionally, the large increase in resource utilisation in the year prior to IPF diagnosis is evidence of the potential benefits to refining the diagnostic procedures.
P3.01-050 Isolation and Characterization of Lymphatic Endothelial Cells from Neoplastic and Normal Human Lung
Authors: Federico Quaini, Bruno Lorusso, Angela Falco, Denise Madeddu, Costanza Lagrasta, Giovanni Bocchialini, Giulia Mazzaschi, Andrea Gervasi, Stefano Cavalli
Journal: Journal of Thoracic Oncology (2017)
P55 Benefits of tiotropium/olodaterol on symptoms and health-related quality of life in patients with moderate to severe COPD with chronic bronchitis and/or emphysema
Authors: GT Ferguson, R Abrahams, L Bjermer, L Grönke, F Voß, D Singh
Journal: Thorax (2016)

<h3>Rationale</h3> Chronic bronchitis and emphysema are common features of chronic obstructive pulmonary disease (COPD), and are associated with adverse symptoms and poor health-related quality of life. The efficacy and safety of the combination of tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β<sub>2</sub>-agonist, has previously been established in COPD. This <i>post hoc</i> analysis of data from two Phase III studies was conducted to assess the effects of this combination on lung function, symptoms and health-related quality of life in patients with COPD with chronic bronchitis and/or emphysema. <h3>Methods</h3> In two replicate, double-blind, parallel-group, placebo-controlled trials (OTEMTO<sup>®</sup> 1 and 2), patients with COPD (GOLD 2–3) were randomised to receive T/O 5/5 µg, T/O 2.5/5 µg, T 5 µg or placebo (P) for 12 weeks via Respimat<sup>® </sup>inhaler.1 Patients were classified as having chronic bronchitis, emphysema or both based on the investigator’s clinical judgement. Lung-function testing was performed during the studies and forced expiratory volume in 1 second (FEV<sub>1</sub>) area under the curve from 0–3 hours (AUC<sub>0–3</sub>) and trough FEV<sub>1</sub> responses (i.e., change from baseline) calculated. Patients also completed the St George’s Respiratory Questionnaire (SGRQ) and the Mahler Transition Dyspnoea Index (TDI). Comparisons between T/O 5/5 µg, T 5 µg and P at Week 12 are reported here. <h3>Results</h3> The numbers of patients included in the analysis were as follows: bronchitis, 506; emphysema, 476; both bronchitis and emphysema, 206. The baseline characteristics of these three groups were generally comparable. After 12 weeks of treatment, there were significant improvements in FEV<sub>1</sub> AUC<sub>0–3</sub> and trough FEV<sub>1</sub> in all groups, with similar improvements across the groups. Significant improvements in SGRQ and TDI occurred in all groups at Week 12 and, again, these seemed to be similar (Table). <h3>Conclusions</h3> T/O 5/5 µg resulted in significant improvements in lung function, dyspnoea and health-related quality of life in patients with moderate to severe COPD with bronchitis, emphysema or both bronchitis and emphysema. <h3>Reference</h3> Singh D, <i>et al</i>. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. <i>Respir Med</i> 2010;<b>109</b>(10):1312–9. <h3>Funding</h3> Boehringer Ingelheim. Please refer to page A271 for declarations of interest in relation to abstract P55.
P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
Authors: Jungmin Choi, Ryan Sowell, Anna Truini, Kurt Schalper, Anna Wurtz, Guoping Cai, Curtis Perry, Ila Datar, Katherine Hastings, Mary Ann Melnick, Edward Kaftan, Paula Kavathas, Susan Kaech, David Rimm, Sarah Goldberg, Anne Chiang, Richard Lifton, Lieping Chen, Roy Herbst, Katerina Politi, Scott Gettinger
Journal: Journal of Thoracic Oncology (2017)
E-cigarettes and Urologic Health: A Collaborative Review of Toxicology, Epidemiology, and Potential Risks
Authors: Liam Bourke, Linda Bauld, Christopher Bullen, Marcus Cumberbatch, Edward Giovannucci, Farhad Islami, Hayden McRobbie, Debra T. Silverman, James W.F. Catto
Journal: European Urology (2017)
The time is right for an international primary ciliary dyskinesia disease registry
Authors: Kenan Haver
Journal: European Respiratory Journal (2017)

Rare diseases present diagnostic and management challenges to patients, healthcare providers and researchers. These diseases are often inherited, typically diagnosed upon presentation during childhood and can have deleterious long-term effects on patient wellbeing [1]. According to the regulatory and policy definition, a rare disease is any condition or disease affecting <200 000 individuals in the USA or in the European Union determined to be of low prevalence (fewer than five affected individuals per 10 000) [2]. With >7000 rare diseases estimated to affect ∼25 million people in North America and 30 million people in Europe [3, 4], even large medical centres are unlikely to have garnered sufficient patient care experience to accurately identify and effectively manage patients with these rare disorders. Diagnostic consensus is a crucial first step toward better understanding of PCD <http://ow.ly/vp8j306eL8z>
The Experience of Hematopoietic Stem Cell Transplantation From An Emerging Centre in North India.
Authors: Satya Prakash Yadav, Manas Kalra, Anupam Sachdeva, Veronique Dinand, Nirbhay Parashar, Sangeeta Kohli, Dharma R Choudhary, Shyam Aggarwal
Journal: Blood (2009)